Market Place
Sourcing Support
FDA Confirms Paragraph IV Patent Litigation for Cysteamine Bitartrate
08 Feb 2022 //
FDA
Enforcement Report - Week of October 21, 2020
21 Oct 2020 //
FDA
Horizon Pharma`s Cysteamine Bitartrate Receives Approval in US
20 Feb 2020 //
FDA
Recordati to seek Canadian approval for kidney disease drug
18 Apr 2019 //
REUTERS
Canadian Government is Investigating Price of Genetic Disease Treatment
27 Mar 2018 //
RAPS
Horizon Completes Sale of EU Mkt Rights for PROCYSBI®&QUINSAIR™ in Europe Chiesi
23 Jun 2017 //
PRESS RELEASE
Horizon Announces Health Canada Approval of PROCYSBI™Cysteamine
19 Jun 2017 //
PRESS RELEASE
Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI
23 May 2017 //
NASDAQ
More Rare Disease Deal making to Follow Horizon`s Raptor Deal
13 Sep 2016 //
THE STREET
Raptor Pharma to stop developing liver drug, shares slump
15 Sep 2015 //
REUTERS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.